Clinical Trials Logo
  1. Home
  2. Allergic Asthma
  3. NCT01019291
  4. Details
NCT01019291 Clinical Trial

Role of Indoor Pollutants on House Dust Mite Allergic Asthma

Allergic Asthma Clinical Trial

Official title:
Aldehyde and Nitrogen Dioxide at Homes: Measurement of the Exposure and Their Role on Allergic Asthma

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT01019291
Other study ID # 3965
Secondary ID
Status Withdrawn
Phase N/A
First received November 23, 2009
Last updated March 26, 2015

Study information
Verified date March 2015
Source University Hospital, Strasbourg, France
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Interventional

Clinical Trial Summary

It seems that the aldehydes and NO2, at the levels found indoor, could be the aggravating factors for an allergic response. However this effect has not been demonstrated. The investigators plan to study the effect of exposure to standard doses of these pollutants on the bronchial reactivity as measured by bronchial challenge tests with dust mite extract in volunteers asthmatic, allergic to house dust mite.

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 50 Years
Eligibility Inclusion criteria:

- M/F 18-50 years of age

- History of intermittent HDM allergic asthma-FEV1 > 80%

- Non smokers or smokers with smoking < 10 PY

Exclusion criteria:

- Persistent asthma and FEV1<80%

- Allergic to pets and pets at home

Study Design

Allocation: Randomized, Masking: Double Blind (Subject, Investigator)

Related Conditions & MeSH terms

Intervention

Other:
• Formaldehyde and NO2 (Exposure to indoor pollutants)
Exposure to indoor pollutants (Formaldehyde and NO2) in a randomized way, followed by bronchial challenge test with house dust mite extract.
• Placebo (Exposure to indoor pollutants)
Exposure to indoor pollutants (placebo) in a randomized way, followed by bronchial challenge test with house dust mite extract.

Locations
Country Name City State
France Unité de Pneumologie, d'Allergologie et de Pathologie Respiratoire de l'Environnement, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg Strasbourg

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

See also
  Status Clinical Trial Phase
Completed NCT03850626 - Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
Completed NCT02911688 - Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure Phase 2
Active, not recruiting NCT01776177 - The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy N/A
Completed NCT00485576 - Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma Phase 2
Completed NCT00515775 - Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children N/A
Completed NCT00736801 - Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma N/A
Completed NCT04259164 - Anti-inflammatory Effects Glycopyrronium Phase 3
Active, not recruiting NCT04619017 - Airway Immune Response to Allergens (Use Lay Language Here) Phase 1
Completed NCT01699594 - Change in Airway Responsiveness After Allergen Exposure N/A
Completed NCT01353755 - 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma Phase 3
Completed NCT00999466 - The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen Phase 2
Completed NCT00434434 - A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma Phase 2
Completed NCT00492076 - Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma Phase 4
Completed NCT00829179 - Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma Phase 3
Completed NCT00490425 - Prevention of Asthma and Allergy by Probiotic Lactobacillus GG Phase 4
Recruiting NCT04542902 - Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma N/A
Recruiting NCT04109534 - Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With Asthma N/A
Active, not recruiting NCT05186025 - Tyrosine Allergoid Paediatric and Adult Study
Withdrawn NCT03307278 - House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance N/A
Enrolling by invitation NCT06151938 - Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis